drug
(latanoprost + netarsudil mesylate)
Marketedupdated 3mo agoby $ALC ALCON INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (latanoprost + netarsudil mesylate)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 27, 2030
~3.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (17)
- Mar 14, 2034compositionUS 10588901
- Mar 14, 2034method-of-use (U-1524)US 11020385
- Mar 14, 2034formulationUS 11185538
- Mar 14, 2034formulationUS 11197853
- Mar 14, 2034compositionUS 9415043
- Mar 14, 2034compositionUS 9931336
- Mar 14, 2034compositionUS 9993470
- Nov 10, 2030compositionUS 83948264.3y
- Jan 27, 2030compositionUS 101740173.5y
- Jan 27, 2030compositionUS 106548443.5y
- Jan 27, 2030method-of-use (U-1524)US 110280813.5y
- Jan 27, 2030method-of-use (U-1524)US 116187483.5y
- Jul 11, 2026method-of-use (U-1524)US 10532993
- Jul 11, 2026method-of-use (U-1524)US 10882840
- Jul 11, 2026method-of-use (U-1524)US 11021456
- Jul 11, 2026compositionUS 8450344
- Jul 11, 2026compositionUS 9096569
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that